Development and Evaluation of Nanolipid Carriers for Solubility Enhancement of Poorly Water-Soluble Drugs: A Comprehensive Review

Abstract

Poor aqueous solubility continues to be one of the most formidable barriers in the development of new drug molecules, leading to poor dissolution, low bioavailability, and inconsistent therapeutic response. Approximately 40–60% of newly synthesized drug candidates fall under the category of poorly water-soluble compounds, belonging primarily to Biopharmaceutics Classification System (BCS) Class II and IV. Nanotechnology-based delivery systems, particularly Nanolipid Carriers (NLCs), have emerged as a highly effective approach for improving the solubility and oral absorption of such drugs. NLCs are the second generation of lipid nanoparticles, developed to overcome the limitations of Solid Lipid Nanoparticles (SLNs), offering higher drug loading, enhanced stability, and controlled release. This review provides a comprehensive overview of the development, formulation strategies, evaluation parameters, and applications of NLCs for solubility enhancement. Emphasis is placed on formulation design, optimization approaches, characterization techniques, and in vitro–in vivo correlations. The article also discusses toxicity, safety, and regulatory aspects of NLCs, highlighting their potential for clinical translation.

Keywords

Nanolipid carriers, Solubility enhancement, Poorly water-soluble drugs, Solid lipid nanoparticles, Bioavailability, Drug delivery, Nanosystems.

Introduction

The solubility of a drug is a key determinant of its absorption and bioavailability following oral administration. Drugs with poor aqueous solubility often exhibit inadequate dissolution rates in gastrointestinal fluids, leading to suboptimal therapeutic efficacy and high interindividual variability. The Biopharmaceutics Classification System (BCS) classifies drugs into four categories based on their solubility and permeability characteristics. Drugs belonging to BCS Class II (low solubility, high permeability) and BCS Class IV (low solubility, low permeability) are particularly problematic, as their poor dissolution limits their systemic availability even when permeability is adequate.

Pharmaceutical scientists have long been exploring a variety of approaches to enhance drug solubility and dissolution rates. These include particle size reduction (micronization, nanonization), use of surfactants, solid dispersions, complexation with cyclodextrins, pH modification, and use of co-solvents. While these conventional methods have demonstrated partial success, they often suffer from drawbacks such as limited stability, poor scalability, and loss of crystallinity upon storage. Consequently, the focus has shifted toward lipid-based drug delivery systems, which not only enhance solubility but also improve permeability and bioavailability.

Lipid nanocarriers have evolved significantly over the past two decades. Early systems such as liposomes and emulsions laid the groundwork for lipid-based formulations. However, they presented issues related to physical instability and leakage of encapsulated drugs. Later, Solid Lipid Nanoparticles (SLNs) were introduced to address these limitations. Although SLNs provided better stability, they were often associated with low drug loading capacity and potential expulsion of drug molecules during lipid recrystallization. To overcome these challenges, Nanolipid Carriers (NLCs) were developed as the second generation of lipid nanoparticles, offering a more flexible and efficient drug delivery platform.

NLCs are typically composed of a mixture of solid and liquid lipids, stabilized by suitable surfactants. This unique matrix structure introduces imperfections in the crystalline lattice of the lipid core, enabling higher drug accommodation and minimizing drug expulsion during storage. The presence of both solid and liquid lipid phases facilitates improved solubilization of lipophilic drugs, controlled release behavior, and better long-term stability.

The significance of NLCs extends beyond solubility enhancement. Their nanoscale particle size ensures a larger surface area, enhancing dissolution kinetics and improving drug diffusion across biological membranes. Furthermore, the lipid matrix mimics physiological lipids, facilitating uptake via lymphatic pathways and reducing first-pass metabolism. NLCs thus represent a promising carrier system for improving oral bioavailability, reducing dosing frequency, and enhancing patient compliance.

The present review aims to provide a detailed and critical overview of NLCs, covering their formulation design, preparation techniques, characterization, applications, limitations, and future prospects. The focus is specifically on their utility in enhancing the solubility and bioavailability of poorly water-soluble drugs — a persistent challenge in modern pharmaceutics

2. Nanolipid Carriers (NLCs): A Comprehensive  Overview

2.1 Evolution of Lipid-Based Nanocarriers

The concept of lipid-based nanocarriers originated from the development of liposomes in the 1960s, which were initially explored for encapsulating hydrophilic and lipophilic drugs. Although liposomes represented a breakthrough in drug delivery, they suffered from issues such as instability, phospholipid oxidation, and drug leakage during storage. This led to the exploration of more stable lipid nanocarriers.

In the early 1990s, Solid Lipid Nanoparticles (SLNs) emerged as an alternative to liposomes and polymeric nanoparticles. SLNs were formulated using physiological lipids, thereby minimizing toxicity while enhancing drug stability. However, SLNs exhibited limitations, including low drug loading capacity and drug expulsion during storage due to lipid recrystallization and polymorphic transitions.

To address these shortcomings, Nanolipid Carriers (NLCs) were developed as the second generation of lipid nanoparticles. NLCs are composed of a blend of solid and liquid lipids, forming a less ordered crystalline matrix that allows greater drug incorporation and prevents drug leakage. This modification resulted in improved stability, drug loading, and release characteristics, making NLCs a preferred choice over SLNs.

2.2 Structural Composition of NLCs

Nanolipid carriers are typically composed of three main components:

1. Solid Lipids – These form the structural backbone of the NLC matrix and provide rigidity. Common examples include glyceryl monostearate, stearic acid, cetyl palmitate, tripalmitin, and glyceryl behenate.
2. Liquid Lipids (Oils) – Also referred to as “oily lipids,” they create imperfections in the crystalline lattice, increasing the capacity for drug accommodation. Examples include oleic acid, medium-chain triglycerides (MCT), caprylic/capric triglycerides, and isopropyl myristate.
3. Surfactants and Co-Surfactants – These stabilize the nanoparticles and prevent aggregation by reducing interfacial tension. Typical surfactants include Poloxamer 188, Tween 80, sodium cholate, and soy lecithin. Sometimes, co-surfactants such as butanol or ethanol are added to enhance dispersion stability.

The ratio of solid to liquid lipids is crucial in determining the internal structure, particle size, and drug release behavior of NLCs. The matrix typically contains 70–90% solid lipid and 10–30% liquid lipid, although the exact ratio depends on the physicochemical nature of the drug and lipid components.

2.3 Types of Nanolipid Carriers

Depending on the structural organization of the lipid matrix and the distribution of the drug within it, NLCs are categorized into three main types:

1. Imperfect-Type NLCs: These are produced by mixing spatially incompatible lipids (solid + liquid lipids), leading to a highly disordered matrix. The imperfections in the crystalline lattice allow more space for the drug to be accommodated, resulting in higher drug loading and reduced risk of expulsion during storage.
   Example: A mixture of glyceryl monostearate and oleic acid.
2. Multiple-Type NLCs: These contain tiny oil nanocompartments within the solid lipid matrix. During the cooling phase of formulation, phase separation occurs, forming oil droplets that act as reservoirs for the drug. This structure is particularly beneficial for achieving sustained release and for accommodating both hydrophilic and lipophilic drugs.
3. Amorphous-Type NLCs: These are designed to avoid any crystalline structure formation by using special lipids that do not recrystallize upon cooling (e.g., hydroxyoctacosanylhydroxystearate). The amorphous matrix prevents drug expulsion and enhances stability during storage.

2.4 Mechanism of Solubility Enhancement

NLCs enhance solubility and bioavailability of poorly water-soluble drugs through multiple mechanisms:

• Increased Surface Area: The nanosized particles provide a larger surface area for dissolution, accelerating the rate at which the drug interacts with the dissolution medium.
• Improved Wettability: Surfactants used in NLCs increase the wettability of the drug particles, further improving solubilization.
• Lipid Solubilization: The lipid matrix provides a hydrophobic environment that enhances the solubility of lipophilic drugs and maintains them in a solubilized state during storage and absorption.
• Lymphatic Uptake: Lipid nanoparticles can be absorbed via intestinal lymphatic pathways, bypassing hepatic first-pass metabolism and improving systemic bioavailability.
• Controlled Drug Release: The combination of solid and liquid lipids enables sustained release, ensuring prolonged therapeutic action.

2.5 Advantages of Nanolipid Carriers

• Enhanced solubility and dissolution rate of poorly soluble drugs.
• High drug loading capacity compared to SLNs.
• Protection of labile drugs from degradation.
• Controlled and sustained drug release.
• Improved physical stability and lower risk of drug expulsion.
• Biocompatibility and biodegradability of lipid components.
• Potential for large-scale industrial production using GRAS (Generally Recognized as Safe) excipients.

2.6 Limitations and Challenges

Despite their advantages, NLCs are not free from challenges:

• Optimization of lipid composition and surfactant concentration is complex and drug-specific.
• Physical instability such as aggregation and polymorphic transitions may occur over time.
• Sterilization and scale-up processes may alter particle characteristics.
• Limited drug release from highly stable lipid matrices in some cases.

Nevertheless, ongoing research continues to refine formulation approaches and analytical techniques to overcome these limitations

3. Methods of Preparation of Nanolipid Carriers (NLCs)

The preparation of Nanolipid Carriers (NLCs) involves careful selection of lipid components, surfactants, and processing parameters to achieve the desired particle size, drug loading, and stability. A variety of preparation methods have been developed to fabricate NLCs with different characteristics. The most widely used techniques include high-pressure homogenization, ultrasonication, solvent emulsification-evaporation, microemulsion, and solvent diffusion methods. Each method offers specific advantages and limitations depending on the drug’s physicochemical properties and the intended application.

3.1 High-Pressure Homogenization (HPH)

High-pressure homogenization is one of the most common and scalable methods for the preparation of NLCs. It operates on the principle of applying intense mechanical shear to a pre-emulsion of molten lipids and aqueous surfactant solution. Two main variants are used: hot homogenization and cold homogenization.

3.1.1 Hot Homogenization

In this method, both the lipid phase and the aqueous phase are heated above the melting point of the lipid (usually 5–10°C higher). The drug is dissolved or dispersed in the melted lipid phase, which is then mixed with the hot aqueous surfactant solution to form a coarse pre-emulsion using high-speed stirring. This pre-emulsion is subsequently passed through a high-pressure homogenizer (500–1500 bar) for several cycles, resulting in the formation of nanosized lipid droplets. Upon cooling to room temperature, the lipid droplets solidify, yielding stable NLCs.

Advantages:

• Suitable for both lipophilic and slightly hydrophilic drugs.
• Produces small particle sizes (<200 nm).
• Solvent-free and easily scalable.

Limitations:

• Possible degradation of thermolabile drugs due to high temperature.
• Incomplete control of particle size distribution if not optimized.

3.1.2 Cold Homogenization

This technique is used to minimize thermal degradation of heat-sensitive drugs. The drug-loaded lipid melt is rapidly cooled using liquid nitrogen or dry ice to solidify it. The solid mass is then ground into microparticles, which are dispersed in a cold aqueous surfactant solution and subjected to high-pressure homogenization at or below room temperature.

Advantages:

• Suitable for thermolabile and hydrophilic drugs.
• Prevents drug partitioning into the aqueous phase during homogenization.

Limitations:

• Larger particle size than hot homogenization.
• Requires additional processing steps like milling.

3.2 Ultrasonication or High-Shear Homogenization

Ultrasonication involves the use of ultrasonic waves (20–40 kHz) to break down coarse emulsions into nanosized droplets. The process typically starts by mixing the melted lipid phase containing the drug with an aqueous surfactant phase at elevated temperatures. The pre-emulsion is then subjected to probe sonication for a specified duration to achieve nanoscale dispersion, followed by cooling to solidify the lipid matrix.

Advantages:

• Simple, cost-effective, and requires minimal equipment.
• Suitable for small-scale laboratory formulations.

Limitations:

• Possible metal contamination from the sonication probe.
• Difficult to scale up for industrial production.
• Limited control over uniformity of particle size.

3.3 Solvent Emulsification-Evaporation Method

In this approach, the lipid and the drug are dissolved in a water-immiscible organic solvent (e.g., chloroform, dichloromethane, or ethyl acetate). This organic phase is emulsified into an aqueous phase containing a surfactant under constant stirring to form an oil-in-water (O/W) emulsion. The organic solvent is then evaporated under reduced pressure, resulting in the precipitation of lipid nanoparticles in the aqueous medium.

Advantages:

• Avoids high temperatures, suitable for thermosensitive drugs.
• Produces small, uniform particles.

Limitations:

• Requires complete removal of organic solvents to avoid toxicity.
• Environmental concerns due to solvent use.
• Not ideal for large-scale manufacturing.

3.4 Microemulsion-Based Method

This method is based on the spontaneous formation of a microemulsion (a thermodynamically stable mixture of oil, water, and surfactants) at a specific composition and temperature. The lipid and drug are first melted together, and then mixed with an aqueous surfactant/co-surfactant mixture to form a clear microemulsion. The hot microemulsion is rapidly dispersed into cold water under constant stirring, leading to precipitation of nanoparticles due to lipid solidification.

Advantages:

• Simple, reproducible, and easy to scale up.
• Produces small particle sizes (50–200 nm).

Limitations:

• Requires large quantities of surfactants and co-surfactants.
• Sensitive to composition and temperature variations.

3.5 Solvent Diffusion Method

Here, both solid and liquid lipids are dissolved in a partially water-miscible organic solvent such as ethanol or acetone. This organic phase is gradually injected into an aqueous phase containing surfactants under constant stirring. As the solvent diffuses into the aqueous phase, the lipids precipitate as nanoparticles. The solvent is later removed by evaporation.

Advantages:

• Mild processing conditions suitable for sensitive drugs.
• Good control over particle size.

Limitations:

• Solvent residues must be completely removed.
• Limited scalability compared to HPH.

3.6 Comparison of Different Preparation Methods

Method	Temperature Requirement	Solvent Use	Scalability	Particle Size (nm)	Suitable for
Hot Homogenization	High	No	Excellent	50–200	Lipophilic drugs
Cold Homogenization	Low	No	Good	100–500	Thermolabile drugs
Ultrasonication	Moderate	No	Moderate	100–300	Lab-scale use
Solvent Evaporation	Low	Yes	Poor	100–200	Thermosensitive drugs
Microemulsion	Moderate	Minimal	Excellent	50–200	Broad applications
Solvent Diffusion	Low	Yes	Moderate	80–250	Sensitive drugs

In conclusion, the selection of the preparation method depends on factors such as drug solubility, thermal sensitivity, desired particle size, and scale of production. Among these, high-pressure homogenization and microemulsion techniques are the most commonly employed in pharmaceutical research and industrial manufacturing of NLCs.

4. Formulation Design and Optimization Parameters

The successful development of Nanolipid Carriers (NLCs) requires a systematic approach to formulation design. The physicochemical characteristics of the drug, lipids, surfactants, and process variables directly influence particle size, zeta potential, entrapment efficiency, drug release, and overall stability. Hence, careful selection and optimization of formulation components are critical for obtaining reproducible and effective NLC formulations.

4.1 Selection of Lipids

Lipids form the structural core of NLCs, determining their physicochemical behavior, drug compatibility, and release profile. The lipid selection depends on the solubility of the drug, the melting point of the lipid, and the intended route of administration.

4.1.1 Solid Lipids

Solid lipids constitute the rigid matrix of the NLC system, solid at both room and body temperature. They influence the crystallinity, polymorphism, and drug entrapment behavior. Commonly used solid lipids include:

• Glyceryl monostearate (GMS)
• Stearic acid
• Tripalmitin
• Cetyl palmitate
• Glyceryl behenate (Compritol® 888 ATO)
• Hydrogenated palm oil

These lipids are selected based on drug solubility in the molten lipid, their biocompatibility, and Generally Recognized as Safe (GRAS) status.

4.1.2 Liquid Lipids (Oils)

Liquid lipids are incorporated to create imperfections in the crystal lattice, increasing drug loading and preventing drug expulsion during storage. Typical examples include:

• Oleic acid
• Caprylic/capric triglycerides (Miglyol® 812)
• Isopropyl myristate
• Medium-chain triglycerides (MCT oil)
• Squalene

A proper balance between solid and liquid lipids (usually 70:30 or 80:20 w/w) ensures structural stability and optimal drug incorporation.

4.1.3 Drug–Lipid Compatibility

Compatibility studies between the drug and selected lipids are essential before formulation. Differential Scanning Calorimetry (DSC), Fourier-Transform Infrared Spectroscopy (FTIR), and X-ray Diffraction (XRD) are typically employed to assess potential chemical interactions and confirm miscibility. Incompatible lipids may lead to phase separation or poor drug entrapment.

4.2 Selection of Surfactants and Co-surfactants

Surfactants stabilize NLCs by reducing interfacial tension between the lipid and aqueous phases. The type and concentration of surfactant affect particle size, zeta potential, and long-term stability.

Common surfactants used in NLC formulation include:

• Poloxamer 188
• Tween 80 (Polysorbate 80)
• Sodium deoxycholate
• Soy lecithin
• Span 80

Co-surfactants, such as butanol, ethanol, or propylene glycol, may be added to improve emulsification efficiency and reduce particle aggregation.

An optimal surfactant concentration is crucial; insufficient surfactant leads to aggregation, while excessive surfactant may cause toxicity or destabilization through micelle formation.

4.3 Effect of Process Variables

The process parameters significantly influence the physicochemical attributes of NLCs.

Parameter	Effect on NLC Properties
Homogenization pressure	Higher pressure reduces particle size but may cause leakage of drug if too intense.
Number of cycles	Increases uniformity and stability up to an optimal point (typically 3–5 cycles).
Temperature of homogenization	Must be above the melting point of lipid; excessive heat can degrade thermolabile drugs.
Cooling rate	Rapid cooling promotes smaller, more stable particles; slow cooling may cause aggregation.

Fine-tuning these parameters is essential to achieving the desired particle size distribution and drug release profile.

4.4 Formulation Optimization Approaches

Modern formulation design increasingly relies on Quality by Design (QbD) and Design of Experiments (DoE) principles to identify critical formulation and process variables systematically.

4.4.1 Factorial Design

This approach allows the study of multiple variables simultaneously, such as lipid concentration, surfactant concentration, and homogenization pressure. It helps determine main effects and interaction effects on key responses (e.g., particle size, zeta potential, and entrapment efficiency).

4.4.2 Response Surface Methodology (RSM)

RSM provides a mathematical and statistical tool for optimizing formulations with fewer experiments. The Box–Behnken Design (BBD) and Central Composite Design (CCD) are frequently used models for NLC optimization, allowing prediction of the optimal formulation with minimal experimental runs.

4.4.3 Desirability Function

This function combines multiple responses (e.g., minimum particle size, maximum entrapment efficiency, controlled release) into a single numerical desirability score to identify the most favorable formulation composition.

4.5 Evaluation of Drug–Excipient Compatibility

Compatibility between the drug and excipients ensures the physicochemical stability of the formulation. Key analytical methods include:

• Fourier Transform Infrared Spectroscopy (FTIR): To detect chemical interactions by observing changes in characteristic peaks.
• Differential Scanning Calorimetry (DSC): To study thermal transitions and confirm drug entrapment within the lipid matrix.
• X-ray Diffraction (XRD): To determine the crystalline or amorphous nature of the drug and lipids after formulation.

The results from these studies guide the selection of compatible excipients and stable formulations.

4.6 Pre-Formulation Studies

Pre-formulation studies help determine critical drug characteristics influencing NLC formulation, such as:

• Drug solubility in various lipids.
• Partition coefficient (Log P).
• Melting point and stability.
• pKa and pH-dependent solubility.

These data guide the rational design of the lipid matrix and selection of surfactants.

4.7 Stability Considerations in Formulation Design

The stability of NLCs is influenced by lipid crystallinity, surfactant concentration, and particle aggregation. The formation of metastable or polymorphic forms can lead to drug expulsion during storage. Proper selection of lipid mixtures and storage conditions (temperature and humidity) can minimize these risks.

Stabilizers such as Poloxamer 188 and Tween 80 are often employed to prevent coalescence and Ostwald ripening. Additionally, storage at 4°C is generally preferred to maintain particle integrity and prevent microbial growth.

In summary, the formulation design of NLCs requires an integrated understanding of lipid–drug interactions, surfactant behavior, and process dynamics. A rational, QbD-based optimization strategy not only ensures reproducible product quality but also accelerates the transition from laboratory scale to industrial production

5. Characterization and Evaluation of Nanolipid Carriers (NLCs)

Comprehensive characterization of Nanolipid Carriers (NLCs) is essential to confirm their quality, performance, and reproducibility. The physicochemical properties of NLCs — such as particle size, zeta potential, morphology, entrapment efficiency, crystallinity, and drug release profile — determine their therapeutic efficacy, stability, and bioavailability. A range of analytical techniques is used to evaluate these attributes both qualitatively and quantitatively.

5.1 Particle Size, Polydispersity Index (PDI), and Zeta Potential

5.1.1 Particle Size and PDI

The mean particle size and polydispersity index (PDI) are critical parameters that affect drug release, absorption, and stability. Smaller nanoparticles provide a larger surface area, enhancing dissolution rate and absorption across biological membranes.

• Technique Used: Dynamic Light Scattering (DLS) or Photon Correlation Spectroscopy (PCS).
• Ideal Range: 50–300 nm with a PDI value below 0.3, indicating uniform particle distribution.
• Influencing Factors: Lipid concentration, surfactant type, homogenization pressure, and cooling rate.

A low PDI ensures homogeneity, while a high PDI (>0.5) indicates agglomeration or non-uniform particle size distribution.

5.1.2 Zeta Potential

Zeta potential measures the surface charge of NLCs and predicts their physical stability. It represents the potential difference between the dispersion medium and the stationary layer of fluid attached to the dispersed particle.

• Technique Used: Electrophoretic light scattering.
• Ideal Range: ±30 mV or higher, indicating good electrostatic stabilization.
• Effect: Higher zeta potential values prevent aggregation due to repulsive forces between similarly charged particles.

Non-ionic surfactants like Poloxamer 188 stabilize NLCs sterically rather than electrostatically, thus maintaining stability even at lower zeta potential values.

5.2 Morphological Analysis

5.2.1 Transmission Electron Microscopy (TEM)

TEM provides detailed visualization of nanoparticle morphology and size at the nanometer scale. NLCs generally appear as spherical or oval-shaped particles with a smooth surface and well-defined boundaries.

5.2.2 Scanning Electron Microscopy (SEM)

SEM offers surface topology and texture information. The images confirm the uniformity and absence of aggregation among nanoparticles.

5.2.3 Atomic Force Microscopy (AFM)

AFM provides three-dimensional surface profiles of nanoparticles, enabling evaluation of surface roughness, height, and particle distribution.

These imaging techniques together help confirm the shape, structure, and surface integrity of the prepared NLCs.

5.3 Entrapment Efficiency (EE) and Drug Loading (DL)

Entrapment efficiency and drug loading determine the proportion of drug successfully incorporated into the lipid matrix.

• Entrapment Efficiency (EE%) = (Amount of drug entrapped / Total drug added) × 100
• Drug Loading (DL%) = (Amount of drug entrapped / Total weight of lipid + drug) × 100

Determination Methods:

1. Ultracentrifugation: The NLC suspension is centrifuged at high speed (e.g., 20,000 rpm for 30–60 min). The supernatant is analyzed spectrophotometrically to determine the unentrapped drug content.
2. Dialysis Method: The NLC dispersion is placed in a dialysis bag and dialyzed against a suitable medium. The drug diffused outside represents the unentrapped fraction.

Factors affecting EE include lipid-to-drug ratio, solubility of the drug in lipid, and surfactant concentration. High liquid lipid content usually improves entrapment due to increased imperfections in the lipid matrix.

5.4 Crystallinity and Polymorphic Behavior

The structural arrangement of lipids affects drug stability and release. Solid lipids may exist in different polymorphic forms (α, β′, and β), each with varying degrees of order and stability. Highly ordered β-forms can expel the drug, whereas less ordered α-forms promote better entrapment.

Analytical Techniques:

• Differential Scanning Calorimetry (DSC): Detects melting points, thermal transitions, and possible interactions between lipid and drug.
• Powder X-Ray Diffraction (PXRD): Determines the crystalline or amorphous nature of the formulation.
• Fourier-Transform Infrared Spectroscopy (FTIR): Identifies possible chemical interactions between drug and excipients through characteristic peak shifts.

A decrease in crystallinity (lower melting enthalpy) after formulation indicates successful incorporation of the drug into the lipid matrix.

5.5 In Vitro Drug Release Studies

In vitro release profiling evaluates how the drug diffuses from NLCs over time, providing insight into release kinetics and mechanism.

Common Methods:

• Dialysis Bag Technique: NLC dispersion is placed in a dialysis membrane and immersed in a release medium (phosphate buffer pH 6.8 or 7.4) under constant agitation. Samples are withdrawn at predetermined intervals and analyzed spectrophotometrically.
• Franz Diffusion Cell: Often used for transdermal formulations, providing controlled diffusion surface area and stirring speed.

Drug Release Kinetics: Drug release data are fitted to mathematical models such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas models to determine the release mechanism. Typically, NLCs exhibit biphasic release: an initial burst phase due to surface-associated drug, followed by sustained release from the lipid core.

5.6 In Vitro Permeation and Diffusion Studies

For oral or topical delivery systems, ex vivo permeation studies using animal membranes (e.g., rat intestinal mucosa or porcine skin) are performed to assess drug permeation efficiency. NLCs generally demonstrate enhanced permeability due to lipid-mediated membrane fluidization and nanoscale size facilitating paracellular transport.

5.7 Stability Studies

Stability testing ensures that NLCs maintain their integrity and performance over time. According to ICH guidelines (Q1A-R2), formulations are stored under specified temperature and humidity conditions:

Condition	Storage Parameters	Duration
Accelerated	40°C ± 2°C / 75% RH ± 5%	3–6 months
Intermediate	30°C ± 2°C / 65% RH ± 5%	6 months
Long-term	25°C ± 2°C / 60% RH ± 5%	12 months

Parameters monitored include:

• Particle size and PDI
• Zeta potential
• Entrapment efficiency
• Drug content
• Visual appearance (aggregation, sedimentation)

Cryoprotectants like mannitol or trehalose may be added during lyophilization to enhance long-term stability.

5.8 Sterility and Safety Testing

For parenteral or ophthalmic formulations, sterility is ensured by aseptic manufacturing or sterile filtration (0.22 µm filters). The absence of endotoxins is verified using the Limulus Amebocyte Lysate (LAL) test.

Cytotoxicity testing (using MTT or trypan blue exclusion assays) on cell lines such as Caco-2 or HEK-293 confirms the biocompatibility of NLCs. Lipid-based systems generally demonstrate low cytotoxicity due to their physiological composition.

5.9 Summary

Comprehensive characterization ensures the quality, safety, and efficacy of NLC formulations. Techniques such as DLS, DSC, TEM, and in vitro release studies provide valuable insights into the structural and functional properties of NLCs. Proper evaluation during development facilitates optimization, regulatory approval, and successful clinical translation.

6. Applications of Nanolipid Carriers in Drug Delivery

Nanostructured lipid carriers (NLCs) have emerged as a versatile platform for the delivery of a wide range of therapeutic agents. Their unique physicochemical and biological properties — such as nanoscale size, biocompatibility, ability to encapsulate both hydrophilic and lipophilic drugs, and capacity to improve bioavailability — make them suitable for multiple routes of administration. The following subsections outline the principal applications of NLCs across various drug delivery systems.

6.1 Oral Drug Delivery

The oral route remains the most convenient and preferred method of drug administration. However, the poor aqueous solubility and low permeability of many active pharmaceutical ingredients (APIs) significantly limit their absorption and bioavailability. NLCs can overcome these limitations through several mechanisms:

• Enhanced solubility: Lipid matrices solubilize lipophilic drugs, improving dissolution rate in gastrointestinal fluids.
• Improved permeability: Lipid nanoparticles interact with intestinal membranes, increasing paracellular and transcellular transport.
• Protection from degradation: NLCs protect labile drugs from acidic gastric environments and enzymatic degradation.
• Lymphatic uptake: Lipid nanoparticles facilitate drug transport through the lymphatic system, bypassing first-pass metabolism.

Examples:

• Curcumin NLCs improved oral bioavailability by more than 5-fold compared to pure drug suspensions.
• Simvastatin-loaded NLCs demonstrated enhanced solubility and prolonged plasma concentration, leading to improved lipid-lowering activity.
• Fenofibrate NLCs achieved higher Cmax and AUC values in pharmacokinetic studies, confirming efficient lymphatic absorption.

Thus, oral NLCs provide a promising strategy for poorly water-soluble drugs classified under BCS Class II and IV.

6.2 Topical and Transdermal Drug Delivery

The stratum corneum acts as a strong barrier to drug permeation, limiting the effectiveness of conventional topical formulations. NLCs enhance drug delivery through the skin via several mechanisms:

• Close contact and occlusion: NLCs form an adherent film over the skin surface, increasing hydration and permeability.
• Skin lipid interaction: The lipid components of NLCs interact with the stratum corneum, disrupting its lipid organization and promoting penetration.
• Controlled release: Sustained drug release from the lipid matrix reduces dosing frequency and local irritation.

Applications:

• Clotrimazole NLC gel exhibited improved antifungal activity and sustained drug release compared to conventional creams.
• Diclofenac sodium NLCs enhanced transdermal permeation and prolonged anti-inflammatory effects.
• Tretinoin NLC formulations minimized skin irritation while maintaining therapeutic efficacy for acne treatment.

NLCs are therefore valuable for dermal and transdermal applications requiring enhanced penetration, controlled release, and improved patient compliance.

6.3 Ocular Drug Delivery

Conventional eye drops face challenges such as poor corneal permeability, rapid tear drainage, and short precorneal residence time. NLCs offer an efficient approach to ocular drug delivery by providing mucoadhesive properties, sustained release, and enhanced drug retention.

Mechanisms of advantage:

• NLCs adhere to the ocular mucosa due to their lipid nature and small particle size.
• The sustained release profile maintains therapeutic drug concentration for extended periods.
• They minimize systemic side effects associated with conventional ophthalmic formulations.

Examples:

• Timolol maleate NLCs demonstrated prolonged intraocular pressure reduction compared to aqueous solutions.
• Dexamethasone NLCs enhanced corneal penetration and anti-inflammatory efficacy with reduced dosing frequency.
• Cyclosporine A NLCs improved bioavailability and patient comfort in the treatment of dry eye syndrome.

Ocular NLCs thus offer a non-invasive, efficient, and patient-friendly alternative to conventional formulations and invasive delivery systems.

6.4 Parenteral Drug Delivery

Intravenous administration of NLCs enables rapid systemic distribution and targeted drug delivery while avoiding first-pass metabolism. Compared with liposomes or polymeric nanoparticles, NLCs provide superior drug stability and reduced burst release.

Advantages:

• High biocompatibility and low toxicity due to physiological lipid components.
• Ability to encapsulate both hydrophobic and hydrophilic drugs.
• Controlled release leading to sustained plasma concentration.
• Potential for surface modification with ligands or antibodies for targeted delivery.

Applications:

• Paclitaxel-loaded NLCs improved solubility and reduced hypersensitivity reactions compared to Cremophor EL-based formulations.
• Docetaxel NLCs achieved superior anticancer activity with reduced systemic toxicity.
• Amphotericin B NLCs enhanced antifungal efficacy with reduced nephrotoxicity.

Parenteral NLCs thus provide a safe and efficient system for delivering potent but poorly soluble drugs, especially in oncology and infectious disease management.

6.5 Pulmonary Drug Delivery

The pulmonary route is gaining attention for both local and systemic drug delivery. NLCs can be incorporated into nebulized or dry powder inhalation systems due to their small size and stability.

Advantages:

• Rapid onset of action through alveolar absorption.
• Bypasses hepatic metabolism.
• Reduces systemic side effects for locally acting drugs.

Examples:

• Budesonide NLCs showed improved lung deposition and prolonged anti-inflammatory effects in asthma therapy.
• Rifampicin-loaded NLCs demonstrated sustained pulmonary retention and enhanced antibacterial efficacy for tuberculosis treatment.

6.6 Targeted Drug Delivery and Cancer Therapy

Targeted NLCs can deliver drugs selectively to specific tissues or cells, minimizing systemic toxicity and enhancing therapeutic efficacy. Targeting is achieved through passive, active, or stimuli-responsive mechanisms.

• Passive targeting: Relies on the Enhanced Permeation and Retention (EPR) effect in tumor vasculature, allowing nanoparticles to accumulate preferentially in cancer tissue.
• Active targeting: Surface modification of NLCs with ligands such as folic acid, antibodies, or peptides enables receptor-mediated uptake by cancer cells.
• Stimuli-responsive targeting: Drug release triggered by pH, temperature, or redox changes within the tumor microenvironment.

Examples:

• Doxorubicin NLCs functionalized with folic acid improved selective uptake by tumor cells and reduced cardiotoxicity.
• Curcumin NLCs enhanced cytotoxicity against breast cancer cells due to improved cellular internalization.
• Camptothecin-loaded NLCs showed prolonged circulation and increased tumor accumulation in animal models.

Thus, NLC-based targeted therapy offers promising outcomes in cancer management by combining site-specific delivery with reduced side effects.

6.7 Brain Targeting and CNS Delivery

The blood–brain barrier (BBB) poses a significant challenge for central nervous system (CNS) drug delivery. Lipid-based nanocarriers can enhance the transport of drugs across the BBB due to their lipophilic nature and small size.

Mechanisms:

• Adsorptive-mediated transcytosis via interaction with endothelial membrane lipids.
• Surface modification with polysorbate 80 or lactoferrin to enhance receptor-mediated transport.
• Protection of drugs from efflux pumps such as P-glycoprotein.

Examples:

• Rivastigmine NLCs improved brain uptake and cognitive efficacy in Alzheimer’s disease models.
• Quetiapine fumarate NLCs enhanced CNS targeting and sustained plasma concentration.
• Resveratrol NLCs increased brain bioavailability and neuroprotective activity.

These systems highlight the potential of NLCs in delivering therapeutic agents to the brain for the treatment of neurodegenerative disorders.

6.8 Other Emerging Applications

• Gene and peptide delivery: NLCs can encapsulate nucleic acids and peptides, protecting them from enzymatic degradation.
• Vaccine delivery: NLCs can act as antigen carriers and adjuvants to enhance immune response.
• Cosmeceuticals: NLCs are used in formulations for anti-aging, skin hydration, and UV protection due to their occlusive and controlled-release properties.

Examples:

• Coenzyme Q10 NLC creams improved antioxidant protection and skin hydration.
• Peptide-loaded NLCs showed prolonged peptide stability in topical applications.

6.9 Summary

Nanostructured lipid carriers have demonstrated versatility across multiple administration routes — oral, transdermal, ocular, pulmonary, parenteral, and targeted delivery. Their ability to enhance solubility, bioavailability, and site-specific delivery positions them as a leading nanotechnology platform in modern pharmaceutics. Continued research into formulation optimization and clinical translation is expected to expand their role in personalized and precision medicine.

7. Recent Advances and Future Prospects of Nanolipid Carriers (NLCs)

The continuous evolution of nanotechnology has significantly refined the design and functionality of nanolipid carriers (NLCs). Beyond basic formulations, current research focuses on smart, hybrid, and targeted NLC systems that can respond to biological stimuli, improve site-specific delivery, and enable large-scale industrial production. These advances aim to translate laboratory success into clinically approved pharmaceutical products.

7.1 Advanced Formulation Strategies

Recent innovations in formulation technology have expanded the versatility of NLCs beyond traditional drug solubilization and sustained release.

7.1.1 Hybrid Nanocarriers

Hybrid systems combine NLCs with other nanocarriers — such as polymers, liposomes, or inorganic nanoparticles — to achieve multifunctionality.

• Polymer–Lipid Hybrid NLCs: These systems integrate biodegradable polymers (e.g., PLGA, chitosan) with lipid cores to improve structural stability, mucoadhesion, and controlled release.
• Lipid–Silica Hybrids: Incorporating mesoporous silica within NLCs enhances mechanical strength and drug loading for poorly soluble molecules.
• Lipid–Metal Nanocomposites: The addition of metallic nanoparticles (e.g., gold or iron oxide) allows for combined therapeutic and diagnostic (“theranostic”) applications, including imaging and hyperthermia therapy.

Such hybrid approaches merge the advantages of multiple nanoplatforms while mitigating their individual limitations.

7.1.2 Stimuli-Responsive and Smart NLCs

Smart NLCs are designed to release their payload in response to specific environmental triggers within the body, such as pH, temperature, redox potential, or enzymatic activity.

• pH-sensitive NLCs: Useful in cancer therapy, where the acidic tumor microenvironment triggers drug release.
• Temperature-sensitive NLCs: Employed for localized hyperthermia-based treatments; drugs are released when exposed to elevated temperatures.
• Redox-responsive systems: Incorporate disulfide linkages that break in high glutathione environments, typical of tumor cells, to enable site-specific drug delivery.
• Enzyme-responsive carriers: Formulated using lipid derivatives cleavable by specific enzymes such as phospholipases or esterases at disease sites.

These systems enhance therapeutic precision, minimize side effects, and are especially promising for oncological and inflammatory diseases.

7.2 Surface Functionalization and Targeting Technologies

Surface modification of NLCs improves their pharmacokinetic profile, cellular uptake, and targeting capability.

7.2.1 Ligand Conjugation

Ligands such as folic acid, transferrin, lactoferrin, peptides, or antibodies can be covalently attached to the NLC surface to enable active targeting via receptor-mediated endocytosis.

For instance, folic acid-conjugated NLCs have shown preferential uptake by folate receptor-positive cancer cells, while transferrin-modified NLCs enhance transport across the blood–brain barrier.

7.2.2 PEGylation

Coating NLCs with polyethylene glycol (PEG) creates a “stealth” layer that reduces recognition and clearance by the reticuloendothelial system (RES). This prolongs circulation time and enhances passive targeting through the enhanced permeation and retention (EPR) effect.

7.2.3 Biomimetic Coatings

Emerging strategies involve coating NLCs with cell membranes (e.g., erythrocyte, platelet, or cancer cell membranes) to mimic biological identity and evade immune detection. These biomimetic NLCs demonstrate superior biocompatibility, prolonged half-life, and site-specific accumulation.

7.3 Advances in Manufacturing Techniques

Scalability and reproducibility are major challenges in transitioning NLCs from lab-scale to commercial production. Modern manufacturing approaches focus on continuous, solvent-free, and energy-efficient methods.

7.3.1 Microfluidics

Microfluidic technology enables precise control over droplet formation and particle size distribution using continuous flow systems. It offers improved reproducibility and scalability compared to conventional homogenization techniques.

7.3.2 Spray-Drying and Lyophilization

Solid-state NLC powders produced through spray-drying or freeze-drying enhance stability and ease of handling. Optimized cryoprotectants prevent particle aggregation and maintain redispersibility upon reconstitution.

7.3.3 Supercritical Fluid Technology

This green and solvent-free technique utilizes supercritical CO? for NLC production, eliminating organic solvent residues and ensuring narrow size distribution with improved encapsulation efficiency.

7.4 Integration with Other Drug Delivery Systems

NLCs are now being integrated with diverse delivery platforms to expand their therapeutic scope.

• Hydrogel–NLC composites: Enhance local retention and provide sustained drug release in topical or injectable formulations.
• Microneedle–NLC systems: Facilitate painless transdermal delivery of vaccines and macromolecules.
• NLC-loaded oral films or capsules: Improve patient compliance and ease of administration for chronic therapies.
• NLCs in 3D-printed dosage forms: Allow personalized drug release profiles tailored to individual patient needs.

Such integrations represent a step toward customized and combination therapies in modern pharmaceutics.

7.5 Regulatory and Commercial Perspectives

Despite substantial research, the number of NLC-based products on the market remains limited due to regulatory challenges, scalability issues, and incomplete understanding of long-term safety.

7.5.1 Regulatory Landscape

NLCs are categorized under nanomedicines, requiring stringent characterization and safety evaluation. Regulatory agencies like the US FDA and EMA emphasize:

• Comprehensive physicochemical characterization (size, zeta potential, morphology).
• Toxicological and biocompatibility assessments.
• Demonstration of batch-to-batch reproducibility.
• Stability and sterility validation under ICH guidelines.

7.5.2 Industrial and Commercial Trends

A few lipid nanoparticle-based drugs, such as Onpattro® (patisiran) and COVID-19 mRNA vaccines, have demonstrated clinical and commercial success, boosting confidence in lipid nanocarrier technology. These milestones pave the way for future NLC-based formulations for both small molecules and biologics.

Pharmaceutical companies are now exploring NLC-based nutraceuticals, cosmetics, and controlled-release injectables, supported by advances in manufacturing and analytical instrumentation.

7.6 Toxicity, Biocompatibility, and Safety Concerns

Although NLCs are composed of physiologically acceptable lipids, their nanoscale nature necessitates rigorous safety evaluation.
Potential concerns include:

• Accumulation in non-target tissues after repeated administration.
• Immunogenic or oxidative stress responses.
• Alteration of normal lipid metabolism upon chronic exposure.

To address these, long-term in vivo toxicity studies and standardized biocompatibility protocols are crucial. Use of natural, biodegradable lipids and avoidance of toxic surfactants (e.g., cationic surfactants) minimize adverse reactions.

7.7 Future Directions

The next generation of NLCs will likely focus on personalized nanomedicine, gene delivery, and multi-drug combination therapies. Integration with artificial intelligence (AI) and machine learning can optimize formulation parameters and predict drug–excipient compatibility.

Promising research trends include:

• AI-driven formulation design for optimizing lipid composition and process parameters.
• mRNA and peptide-loaded NLCs for vaccine and gene therapy applications.
• Theranostic NLCs combining therapy and imaging capabilities.
• Biodegradable NLCs with zero environmental residue for sustainable pharmaceutics.

The convergence of nanotechnology, biotechnology, and data science will redefine the landscape of nanolipid drug delivery in the coming decade.

7.8 Summary

Recent advances in NLC technology have led to more sophisticated, multifunctional, and patient-centric drug delivery systems. With continued progress in formulation science, regulatory clarity, and clinical validation, NLCs hold immense promise for translating laboratory innovation into real-world therapeutic solutions.

8. Challenges, Limitations, and Regulatory Considerations

Despite the remarkable progress and promising potential of nanolipid carriers (NLCs), several scientific, technical, and regulatory challenges still hinder their widespread clinical and commercial application. Understanding these limitations is crucial for optimizing formulation design, ensuring safety, and facilitating regulatory approval.

8.1 Formulation and Stability Challenges

8.1.1 Physical and Chemical Instability

NLCs, being colloidal systems, are prone to aggregation, polymorphic transitions, and drug expulsion during storage. These phenomena can significantly alter particle size, zeta potential, and drug release behavior.

• Particle Aggregation: Caused by insufficient surfactant stabilization or electrostatic charge neutralization over time.
• Polymorphic Transformation: Lipids tend to rearrange into more stable crystalline forms (β-modifications), reducing drug incorporation capacity.
• Drug Leakage: The imperfect lipid matrix may expel entrapped drugs upon storage or temperature fluctuations.

Stabilizers such as poloxamers, tween, or PEGylated lipids can mitigate aggregation, while lyophilization with cryoprotectants like mannitol or trehalose enhances long-term stability.

8.1.2 Scalability Issues

While laboratory-scale preparation of NLCs is well established, scaling up for industrial production poses several difficulties:

• Maintaining consistent particle size distribution and encapsulation efficiency.
• High energy consumption during homogenization or ultrasonication.
• Equipment limitations for continuous large-scale production.

Advanced methods such as microfluidics and supercritical fluid processing are emerging solutions but require high capital investment.

8.1.3 Limited Drug Loading

Highly crystalline solid lipids can only accommodate a limited amount of drug. Excess drug can crystallize outside the matrix, reducing encapsulation efficiency and altering release kinetics. Optimizing the ratio of solid to liquid lipid and using less ordered lipid structures can help enhance drug loading capacity.

8.2 Biological and Safety Concerns

Although NLCs are composed of biocompatible lipids, their nanoscale dimensions raise questions about long-term safety and biodistribution.

8.2.1 Cytotoxicity and Immunogenicity

Some surfactants (e.g., cationic surfactants) may disrupt cell membranes or induce inflammatory responses. Chronic administration can cause lipid accumulation in non-target tissues or interfere with normal lipid metabolism. Comprehensive in vitro cytotoxicity and in vivo biocompatibility studies are therefore essential.

8.2.2 Biodistribution and Clearance

Understanding the pharmacokinetics and biodistribution of NLCs is complex due to their interaction with plasma proteins and the mononuclear phagocyte system (MPS). Rapid clearance by macrophages can limit circulation time and therapeutic efficacy. Surface modification (e.g., PEGylation) helps prolong systemic circulation and reduce RES uptake.

8.2.3 Blood–Brain Barrier and Organ Accumulation

For targeted or CNS applications, there is a risk of non-specific accumulation in the liver, spleen, or kidneys. This necessitates the use of targeted or stimuli-responsive NLCs to minimize off-target effects.

8.3 Analytical and Characterization Limitations

Accurate characterization of NLCs is fundamental for ensuring reproducibility and quality control. However, existing analytical methods face limitations:

• Dynamic Light Scattering (DLS): Provides mean particle size but cannot distinguish between aggregates and single particles.
• Transmission Electron Microscopy (TEM): Time-consuming, expensive, and sample preparation can cause artifacts.
• Drug Distribution Analysis: Determining whether a drug resides in the lipid core or on the surface remains challenging.

Thus, there is a pressing need for standardized analytical protocols combining complementary techniques to ensure reliable characterization.

8.4 Regulatory Challenges

8.4.1 Lack of Standardized Guidelines

Regulatory frameworks for nanomedicines are still evolving. Agencies such as the USFDA, EMA, and ICH have issued general guidelines for nanotechnology-based products, but specific directives for NLCs are lacking. This creates uncertainty in dossier preparation and approval pathways.

8.4.2 Quality by Design (QbD) Approach

Regulators increasingly encourage the application of Quality by Design (QbD) principles to nanocarrier formulations. Critical Quality Attributes (CQAs) such as particle size, zeta potential, and drug loading must be defined and controlled through risk-based approaches and Design of Experiments (DoE).

8.4.3 Safety and Toxicological Evaluation

Comprehensive toxicity studies addressing acute, sub-chronic, and chronic exposure are mandatory. Additionally, immunogenicity, genotoxicity, and reproductive toxicity assessments are often required for nanocarrier-based drugs.

8.4.4 Environmental and Occupational Concerns

Manufacturing and disposal of nanomaterials raise environmental safety concerns. Nanoparticles released into water or air during production may pose ecological risks. Implementation of Good Manufacturing Practices (GMP) and environmental risk assessments are therefore necessary.

8.5 Economic and Translational Barriers

While NLCs offer significant therapeutic benefits, the cost of raw materials, specialized equipment, and complex manufacturing processes limits their commercial viability. Additionally, intellectual property (IP) disputes and the lack of universally accepted bioequivalence standards further hinder their market introduction.

Key barriers include:

• High cost of purification and sterilization.
• Limited stability of aqueous dispersions for long-term storage.
• Insufficient clinical data supporting efficacy and safety.
• Challenges in obtaining consistent regulatory approval across different regions.

Pharmaceutical industries are gradually addressing these issues by investing in scalable manufacturing technologies, automation, and AI-based formulation optimization.

8.6 Strategies to Overcome Challenges

To bridge the gap between research and commercialization, several strategies are being adopted:

• Use of Natural Lipids: Minimizes toxicity and enhances biocompatibility.
• Green Manufacturing Techniques: Employ solvent-free, energy-efficient production processes.
• Improved Analytical Standards: Development of validated, multi-technique characterization protocols.
• Regulatory Collaboration: Harmonization of nanomedicine guidelines between global agencies (FDA, EMA, WHO).
• Long-term Safety Studies: Establish standardized models for chronic toxicity and pharmacokinetic evaluation.
• Economic Optimization: Streamlining formulation and packaging to reduce production costs.

8.7 Summary

While nanolipid carriers represent a breakthrough in the delivery of poorly soluble drugs, challenges related to stability, scalability, regulatory approval, and safety must be systematically addressed. Collaborative efforts among scientists, industry, and regulatory bodies are essential for establishing standard protocols and promoting global acceptance of NLC-based therapeutics. Future advancements in process engineering, analytical techniques, and policy frameworks will play a pivotal role in the successful translation of NLCs from bench to bedside.

CONCLUSION AND FUTURE OUTLOOK

Poor aqueous solubility remains one of the most significant challenges in the development of effective oral and parenteral drug formulations. Over 40% of newly developed chemical entities (NCEs) suffer from inadequate solubility, resulting in poor absorption, suboptimal bioavailability, and inconsistent therapeutic outcomes. Nanolipid carriers (NLCs) have emerged as a powerful and versatile nanotechnological approach to overcome these limitations by combining the advantages of solid lipid nanoparticles (SLNs) and liquid lipid systems.

The amorphous or imperfect crystal structure of NLCs provides sufficient space to incorporate a higher drug load while minimizing expulsion during storage. Their biocompatible lipid composition, controlled release profile, and potential for surface modification make them suitable for a wide range of therapeutic applications. Studies have demonstrated their ability to improve oral bioavailability, enhance skin permeation, and enable targeted and sustained drug delivery across multiple biological barriers. The integration of NLCs into oral, transdermal, ocular, and parenteral formulations has already shown superior pharmacokinetic and pharmacodynamic outcomes compared to conventional systems.

Despite these advantages, several challenges persist, including issues related to long-term stability, scalability of manufacturing, limited regulatory guidelines, and incomplete understanding of long-term safety. Addressing these concerns through systematic research and adherence to regulatory frameworks will be crucial for the successful translation of NLCs into clinical practice.

In the coming years, research focus is expected to shift toward smart and targeted NLCs capable of responding to specific physiological triggers such as pH, temperature, or redox gradients. Surface engineering through ligand conjugation and biomimetic coatings will further enhance site-specific drug delivery and minimize systemic toxicity. Additionally, integration of artificial intelligence (AI) and machine learning (ML) in formulation design will allow predictive optimization of composition, process parameters, and stability outcomes.

The intersection of nanotechnology, biotechnology, and data-driven formulation science is poised to redefine the pharmaceutical landscape. With increasing industrial interest, improved scalability, and growing regulatory clarity, nanolipid carriers hold the potential to revolutionize the delivery of poorly water-soluble drugs and complex biomolecules. Their future lies not only in conventional small-molecule drugs but also in gene therapy, vaccine delivery, and personalized medicine.

In conclusion, nanolipid carriers represent a next-generation drug delivery platform that bridges the gap between formulation science and therapeutic innovation. Continued interdisciplinary collaboration between pharmaceutical scientists, clinicians, and regulatory agencies will pave the way for safer, more effective, and patient-centric nanomedicine solutions. The successful clinical translation of NLC-based formulations will mark a significant step toward achieving enhanced solubility, targeted therapy, and improved global healthcare outcomes.

REFERENCES

1. Choi KO, Choe J, Suh S, Ko S. Positively charged nanostructured lipid carriers and their effect on the dissolution of poorly soluble drugs. Molecules. 2016;21(5):672.
2. Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid lipid nanoparticles vs nanostructured lipid carriers: a comparative review. Pharmaceutics. 2023;15(6):1593.
3. Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics. 2020;12(3):288.
4. Queiroz MCV, Muehlmann LA. Characteristics and preparation of solid lipid nanoparticles and nanostructured lipid carriers. J Nanotheranostics. 2024;5(4):188-211.
5. Shirodkar RK, Kumar L, Mutalik S, Lewis S. Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid-based drug delivery systems. Pharm Chem J. 2019;53(5):440-453.
6. Jain S. An updated review on nanostructured lipid carriers (NLC). BR Nahata Smriti Sansthan Int J Pharm Sci Clin Res. 2022;2(4).
7. Sharma A, Sharma D, Panda PK, Ghosh NS. Solid lipid nanoparticles and nanostructured lipid particles: a comparative review on lipid-based nanocarriers. Pharm Nanotechnol. 2025;13:In press.
8. Nikam ST, Pomaje M, Patil A, Kamat V, Bhagwat R. Nanostructured lipid carriers in drug delivery: a review. Int J Membr Sci Technol. 2023;10(4):2649-2658.
9. Nikam C, Gohil D, Seth A. Nanostructured lipid carriers as an efficient drug delivery carrier. Glob J Nano. 2017;3(3):555614.
10. Negi V. Bioavailability enhancement of poorly soluble drugs using lipid nanoparticles. Int J Res Manag Pharm.
11. Desai M, Dhanna S, Jadhav S, et al. Formulation and evaluation of simvastatin-loaded nanostructured lipid carriers for topical drug delivery. Indian J Pharm Educ Res. 2025;59(2 Suppl):S421–S432.
12. Raj SB, Kothapalli BC, Reddy KB. Formulation, in vitro and in vivo pharmacokinetic evaluation of simvastatin-loaded nanostructured lipid carrier transdermal drug delivery system. Future J Pharm Sci. 2019;5:9.
13. Mousavi-Simakani S, Azadi A, Tanideh N, et al. Simvastatin-loaded nanostructured lipid carriers as topical drug delivery systems for wound healing. Adv Pharm Bull. 2023;13(4):761–771.
14. Elmowafy M, Al-Sanea MMM. Nanostructured lipid carriers as drug delivery platforms: advances in formulation and delivery strategies. Sci Pharm. 2021;89(3):29.
15. Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and targeted drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):27–36.
16. Khan S, Baboota S, Ali J, et al. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182–191.
17. Duong VA, Nguyen TT, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery. Molecules. 2020;25(20):4781.
18. Plaza-Oliver M, Santander-Ortega MJ, Lozano MV. Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv Transl Res. 2021;11(2):471–497.
19. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in drug delivery. Adv Drug Deliv Rev. 2007;59(6):522–530.
20. Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics. Pharmaceutics. 2020;12(3):288.
21. Nimtrakul P, Sermsappasuk P, Tiyaboonchai W. Strategies to enhance oral delivery of drugs via nanostructured lipid carriers. Drug Deliv. 2020;27(1):1054–1062.
22. Shahzadi I, Fürst A, Knoll P, Bernkop-Schnürch A. Nanostructured lipid carriers for oral peptide delivery. Pharmaceutics. 2021;13(8):1312.
23. Tan SLJ, Billa N. Lipid nanoparticles with mucoadhesive properties for improved bioavailability. Pharmaceutics. 2021;13(11):1817.
24. Patil GB, Patil ND, Deshmukh PK, et al. Nanostructured lipid carriers for carvedilol delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):12–19.
25. Yin J, Hou Y, Yin Y, Song X. Selenium-coated nanostructured lipid carriers for enhanced oral delivery of berberine. Int J Nanomedicine. 2017;12:8671–8680.
26. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–580.
27. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems – an overview. Acta Pharm Sin B. 2013;3(6):361–372.
28. Reinholz J, Landfester K, Mailänder V. Challenges of oral drug delivery via nanocarriers. Drug Deliv. 2018;25(1):1694–1705.
29. Garg NK, Tyagi RK, Singh B, Sharma G, Nirbhavane P, Kushwah V, et al. Nanostructured lipid carrier-mediated transdermal delivery of simvastatin for the treatment of hyperlipidemia. Colloids Surf B Biointerfaces. 2016;145:208–216.
30. Dudhipala N, Janga KY, Gorre T. Comparative evaluation of solid lipid nanoparticles and nanostructured lipid carriers for oral delivery of nisoldipine. Artif Cells Nanomed Biotechnol. 2018;46(Suppl 1):616–625.
31. Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers: formulation, optimization and in vivo evaluation. Int J Pharm. 2017;533(1):177–186.
32. Khan S, Baboota S, Ali J. Nanostructured lipid carriers: an emerging platform for oral drug delivery. Int J Pharm Sci Res. 2016;7(4):1528–1541.
33. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–313.
34. Beloqui A, Solinís MÁ, des Rieux A, Préat V, Rodríguez-Gascón A. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine (Lond). 2016;11(11):143–161.
35. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288–303.
36. Duong VA, Nguyen TT, Maeng HJ. Impact of solvent injection parameters on the physicochemical properties of nanostructured lipid carriers. Pharmaceutics. 2020;12(6):547.
37. Khan S, Imran M, Ali J, Baboota S. Nanostructured lipid carriers: an emerging platform for improving bioavailability of lipophilic drugs. J Drug Deliv Sci Technol. 2019;50:413–430.
38. Tran PHL, Tran TTD, Lee BJ. Modulation of lipid nanocarriers for transdermal delivery of poorly water-soluble drugs. Pharmaceutics. 2021;13(3):343.
39. Shah R, Eldridge D, Palombo E, Harding I. Lipid nanoparticles: production, characterization and stability. Pharmaceutics. 2014;6(3):544–571.
40. Tiyaboonchai W. Lipid nanoparticles for drug delivery systems. Songklanakarin J Sci Technol. 2003;25(4):547–559.
41. Fathi M, Shokri J, Akbari J, et al. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B Biointerfaces. 2018;162:236–245.
42. Mousavi-Simakani SM, Azadi A, Tanideh N, et al. Simvastatin-loaded nanostructured lipid carriers as topical drug delivery system for wound healing purposes: preparation, characterization, and in vivo histopathological studies. Adv Pharm Bull. 2023;13(4):761–771.
43. Raj SB, Kothapalli BC, Reddy KB. Formulation, in vitro and in vivo pharmacokinetic evaluation of simvastatin nanostructured lipid carrier loaded transdermal drug delivery system. Future J Pharm Sci. 2019;5:9.
44. Ashtiani SY, Shabani Z, Azizi M, et al. Preparation and safety evaluation of topical simvastatin loaded NLCs for vitiligo. J Pharm Sci. 2021;110(4):1234–1243.
45. Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a review (including examples of statins in NLCs). Pharmaceutics. 2020;12(3):288.
46. Khan S, Sharma A, Baboota S, et al. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182–191. (discusses bioavailability enhancement relevant to statins via NLCs)
47. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–313. (review relevant to NLC design for simvastatin)
48. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, et al. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine (Lond). 2016;11(11):143–161. (general NLC review supporting mechanism)
49. Duong VA, Nguyen TT, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery. Molecules. 2020;25(20):4781.
50. Shahzadi I, Fürst A, Knoll P, Bernkop-Schnürch A. Nanostructured lipid carriers for oral peptide delivery. Pharmaceutics. 2021;13(8):1312. (mechanistic relevance for NLC oral absorption)
51. Nimtrakul P, Sermsappasuk P, Tiyaboonchai W. Strategies to enhance oral delivery via nanostructured lipid carriers. Drug Deliv. 2020;27(1):1054–1062.
52. Plaza-Oliver M, Santander-Ortega MJ, Lozano MV. Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv Transl Res. 2021;11(2):471–497.
53. Patil GB, Patil ND, Deshmukh PK, et al. Nanostructured lipid carriers for carvedilol delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):12–19. (illustrates NLC principles applicable to statins)